Joachim Boos - Concepedia

Author

Joachim Boos

Also Known As

Alexander Rumjanzew, Boos Joachim, Boos, J, Boos, J., D Rosenbaum, J Boos, J. Boos, JOACHIM BOOS, Jana Boos, Joachim Boos

313

Publications

8.8K

Citations

H-Index

121

Concepts

All Affiliations

University Hospital Münster University of Münster Goethe University Frankfurt Charité - Universitätsmedizin Berlin Medizinische Hochschule Hannover

About

Joachim Boos is an author at University Hospital Münster specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	67	2.8K
2	Health Sciences	9	9	335
3	Engineering	2	2	107
4	Natural Sciences	1	1	71
5	Allergy	1	1	122

Joachim Boos

141

Publications

Citations

H-Index

Page 1

	Year	Citations
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Anja Möricke, Alfred Reiter, Martin Zimmermann, Blood	2008	601
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial Frank Berthold, Joachim Boos, Stefan Burdach, The Lancet Oncology Hematological MalignancyNeuro-oncologyCell TherapyAutologous Stem-cell RescueMedicine	2005	397
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations Joachim Boos, G. Werber, E. Ahlke, European Journal of Cancer Asparaginase ActivityAsparagine LevelsDifferent Asparaginase Preparations	1996	217
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma Jane Carr‐Wilkinson, K O’Toole, Katrina Wood, Clinical Cancer Research	2010	163
Level of activity in children undergoing cancer treatment Corinna Winter, Carsten Müller, Mirko Brandes, Pediatric Blood & Cancer	2009	151
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 Ursula Creutzig, J. Ritter, M Zimmermann, Leukemia Hematological MalignancyCell ClearanceHematologyImmunologyStudy Aml-bfm 93	2001	143
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. R. Rossi, Almut Gödde, Almud Kleinebrand, Journal of Clinical Oncology	1994	135
Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity Angela Weirich, R. Ludwig, Norbert Graf, Annals of Oncology UrologyGenitourinary CancerMedicinePathologyCancer Treatment	2004	129
Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors Michael C. Frühwald, Martin Hasselblatt, Karolina Nemes, Neuro-Oncology	2019	129
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS‐96 trial Thomas Klingebiel, Joachim Boos, Florian Beske, Pediatric Blood & Cancer	2008	127

Page 1